Stifel raised the firm’s price target on Becton Dickinson (BDX) to $215 from $210 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is constructive for large-cap MedTech following 2025 pressures, adjusted targets among its coverage and highlights Boston Scientific (BSX), Edwards Lifesciences (EW), and Solventum (SOLV) as its three top ideas entering the year.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target raised to $207 from $190 at BofA
- Becton Dickinson, University of Pennsylvania partner on human immune profiling
- Becton Dickinson price target raised to $210 from $202 at RBC Capital
- Becton Dickinson announces expansion of BD MAX System menu
- Roth Capital healthcare analyst holds an analyst/industry conference call